Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RACE - Rapid Amplification of cDNA Ends02:35

RACE - Rapid Amplification of cDNA Ends

7.3K
Rapid Amplification of cDNA Ends, or RACE, is one of the most effective methods to obtain a full-length cDNA from an mRNA sequence between a known internal region to the unknown sequence at the 5’ or 3’ end. The unknown region is cloned in the cDNA by a gene-specific primer that binds the known end, and a hybrid primer that attaches a predefined anchor sequence to the unknown end of the cDNA. The sequence in between is amplified by PCR with an anchor primer and a gene-specific...
7.3K
Social Scripts02:10

Social Scripts

10.3K
People tend to know what behavior is expected of them in specific, familiar settings. A script is a person’s knowledge about the sequence of events expected in a specific setting (Schank & Abelson, 1977). Essentially, scripts are a particular kind of schema, one containing default values for the features within an event. In the restaurant example, the script's features include the props (e.g., tables, menu, food, and money), the roles to be played (e.g., customer and waiter),...
10.3K
Attitudes01:54

Attitudes

33.2K
Attitude is our evaluation of a person, an idea, or an object. We have attitudes for many things ranging from products that we might pick up in the supermarket to people around the world to political policies. Typically, attitudes are favorable or unfavorable: positive or negative (Eagly & Chaiken, 1993). And, they have three components: an affective component (feelings), a behavioral component (the effect of the attitude on behavior), and a cognitive component (belief and knowledge;...
33.2K
Robbers Cave04:49

Robbers Cave

14.8K
During the 1950s, the landmark Robbers Cave experiment demonstrated that when groups must compete with one another, intergroup conflict, hostility, and even violence may result. At the Oklahoman summer camp, two troops of boys—termed the Rattlers and the Eagles—took part in a week-long tournament. During this time, their negativity culminated in derogatory name-calling, fistfights, and even vandalism and destruction of property. However, this work also revealed that such tension...
14.8K
Trait and State Self-Esteem02:08

Trait and State Self-Esteem

11.5K
The term self-esteem is often used generically, to refer to how people feel about themselves. However, according to research, there are three distinct constructs that should not be used interchangeably (Brown & Marshall, 2006). 
11.5K
First Law of Thermodynamics02:16

First Law of Thermodynamics

40.8K
Energy Conservation
40.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Implications of SMARCA4, ARID1A, and Other BAF Mutations in Non-Small Cell Lung Cancer.

Cancer medicine·2025
Same author

A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Radiomics-Based Prediction of Treatment Response to TRuC-T Cell Therapy in Patients with Mesothelioma: A Pilot Study.

Cancers·2025
Same author

A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.

Nature medicine·2023
Same author

GPRC5D-Targeted CAR T Cells for Myeloma.

The New England journal of medicine·2022

Related Experiment Video

Updated: Jan 28, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.5K

What CAR Will Win the CD19 Race?

Alfonso Quintás-Cardama1

  • 1TCR Therapeutics, Cambridge, Massachusetts. alfonso.quintas@tcr2.com.

Molecular Cancer Therapeutics
|March 3, 2019
PubMed
Summary

Chimeric antigen receptor (CAR) T cell therapy shows promise for B-cell malignancies, with FDA-approved products available. However, challenges like toxicity and antigen escape must be overcome for wider adoption and competitive advantage.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Adoptive T cell therapy using engineered receptors is a novel cancer treatment.
  • Chimeric antigen receptor (CAR) T cell therapy targeting CD19 is advanced in clinical development for B-cell malignancies.

Purpose of the Study:

  • To review the current state of CAR T cell therapy for cancer.
  • To identify limitations and competitive advantages for future CAR T cell products.

Main Methods:

  • Review of clinical development platforms for CAR T cell therapy.
  • Analysis of FDA-approved CAR T cell products and their performance.
  • Identification of challenges associated with current CAR T cell therapies.

Main Results:

More Related Videos

A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.2K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K

Related Experiment Videos

Last Updated: Jan 28, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.5K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.2K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
  • Several CAR T cell platforms demonstrate significant activity in relapsed/refractory B-cell malignancies.
  • The FDA approved the first CAR T cell products in 2017, with more anticipated.
  • CAR T cell therapy faces challenges including toxicity, antigen escape, tumor microenvironment resistance, cost, and access.

Conclusions:

  • CAR T cell therapy is a powerful tool in cancer treatment, particularly for B-cell malignancies.
  • Addressing current limitations is crucial for developing superior CAR T cell products.
  • Future advancements will focus on overcoming toxicity, resistance, and accessibility issues to gain a competitive edge.